Article
Analysis: Amgen's antitrust woes spur wider pharmaceutical deal fears
Rating:
0.0
Views:
60
Likes:
1
Library:
1
Investors are scrambling to assess the fallout of a U.S. regulatory challenge against Amgen Inc's proposed $27.8 billion acquisition of Horizon Therapeutics Plc , with some fearing a spillover to other big deals in the drug sector.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value